Avidicure CEO Arthur Lahr spoke with Nuala Moran of BioWorld News about their $50M seed funding and how AVC-Boosters are designed to activate multiple immune pathways, unlocking powerful responses across both the innate and adaptive immune system. Read the full article to learn how they’re rethinking antibody engineering: https://bit.ly/4kNiZdY
News Dec 16, 2025
Dutch life sciences VC BioGeneration Ventures led TargED’s €21.5 million Series A extension Proceeds will accelerate clinical...